Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2024 Earnings Call Transcript August 8, 2024 8:00 AM ET

Company Participants

Lindsey Allen - Head of Investor Relations and Communications
Justin Klee - Co-Chief Executive Officer
Joshua Cohen - Co-Chief Executive Officer
Camille Bedrosian - Chief Medical Officer
James Frates - Chief Financial Officer

Conference Call Participants

Charlie Yang - Bank of America

Operator

Good morning. My name is Camille, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals' Second Quarter 2024 Earnings Conference Call. All participants will be on a listen-only mode. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]. Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Lindsey Allen, Head Investor Relations and Communications. Please proceed.

Lindsey Allen

Good morning and thank you all for joining us today to discuss our second quarter 2024 financial results. With me on the call today are Joshua Cohen and Justin Klee, our co-CEOs, Dr. Camille Bedrosian, our Chief Medical Officer, and James Frates, our Chief Financial Officer.

Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans, and expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

These statements include, but are not limited to, our expectations with respect to Avexitide, AMX0035 and AMX0114, statements regarding regulatory and clinical developments and the impact thereof and the expected timing thereof, and statements regarding our cash runway. Actual events and results could differ materially from those expressed or implied by any forward-looking statements. You are cautioned not to place any undue reliance on these forward-looking statements, and Amylyx disclaims any obligation to update such statements unless required by law.

Now, I will turn the call over to Justin.

Justin Klee

Good morning and thank you all for joining us today. As an organization, we have made significant progress over the past few months as part of our continued mission and our goal to deliver important treatment options to the neurodegenerative, neuroendocrine, and endocrine communities we serve.

Most notably, last month, we expanded our late-stage pipeline with our acquisition of Avexitide and now have three assets targeting orphan indications. Avexitide is a Phase 3-ready asset with FDA breakthrough therapy designation in diseases with no approved treatment options.